Physician profile
Alec Eldar Musten
NPI 1770725822
$3,304.41
in general payments reported to CMS, 2019-2025
24 companies · $97.43 in 2025
The $97.43 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $84.29 · 2021: $633 · 2022: $687 · 2023: $472 · 2024: $368 · 2025: $97.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,151.43 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $467.81 | 2019-2024 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $288.44 | 2019-2024 | |
| Pfizer INC. | $269.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.55 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.19 | 2021-2025 | Lifevest |
| Abbott Laboratories | $180.60 | 2024 | Mitraclip |
| Boston Scientific Corporation | $110.18 | 2023-2024 | Watchman Access System, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $56.24 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $44.40 | 2019-2022 | |
| Novo Nordisk INC | $40.96 | 2024 | Wegovy, Rybelsus, Ozempic |
| Althera Pharmaceuticals LLC | $32.86 | 2021 | |
| Esperion Therapeutics, INC. | $32.81 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $30.49 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $27.26 | 2023 | Zio Xt Patch |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.00 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.35 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $24.01 | 2021 | |
| Daiichi Sankyo INC. | $21.52 | 2019 | |
| Medtronic, INC. | $19.87 | 2022 | |
| Edwards Lifesciences Corporation | $18.55 | 2019 | |
| Glaxosmithkline, LLC. | $16.15 | 2025 | Shingrix, Arexvy |
| Amgen INC. | $13.53 | 2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Musten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.